CoChat

Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder

Open access
Chen, John J., Flanagan, Eoin P., Bhatti, M. Tariq, Jitprapaikulsan, Jiraporn, Dubey, Divyanshu, Lopez Chiriboga, Alfonso (Sebastian) S., Fryer, James P., Weinshenker, Brian G., McKeon, Andrew, Tillema, Jan-Mendelt, Lennon, Vanda A., Lucchinetti, Claudia F., Kunchok, Amy, McClelland, Collin M., Lee, Michael S., Bennett, Jeffrey L., Pelak, Victoria S., Van Stavern, Gregory, Adesina, Ore-Ofe O., Eggenberger, Eric R., Acierno, Marie D., Wingerchuk, Dean M., Lam, Byron L., Moss, Heather, Beres, Shannon, Gilbert, Aubrey L., Shah, Veeral, Armstrong, Grayson, Heidary, Gena, Cestari, Dean M., Stiebel-Kalish, Hadas, Pittock, Sean J. · 2020 · Neurology
Cited by 233

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) associated disorder (MOGAD) often manifests with recurrent CNS demyelinating attacks. The optimal treatment for reducing relapses is unknown. To help determine the efficacy of long-term immunotherapy in preventing relapse in patients with MOGAD, we conducted a multicenter retrospective study to determine the rate of relapses on various treatments. METHODS: We determined the frequency of relapses in patients receiving various forms of long-term immunotherapy for MOGAD. Inclusion criteria were history of ≥1 CNS demyelinating attacks, MOG-IgG seropositivity, and immunotherapy for ≥6 months. Patients were reviewed for CNS demyelinating attacks before and during long-term immunotherapy. RESULTS: Seventy patients were included. The median age at initial CNS demyelinating attack was 29 years (range 3-61 years; 33% <18 years), and 59% were female. The median annualized relapse rate (ARR) before treatment was 1.6. On maintenance immunotherapy, the proportion of patients with relapse was as follows: mycophenolate mofetil 74% (14 of 19; ARR 0.67), rituximab 61% (22 of 36; ARR 0.59), azathioprine 59% (13 of 22; ARR 0.2), and IV immunoglobulin (IVIG) 20% (2 of 10; ARR 0). The overall median ARR on these 4 treatments was 0.3. All 9 patients treated with multiple sclerosis (MS) disease-modifying agents had a breakthrough relapse on treatment (ARR 1.5). CONCLUSION: This large retrospective multicenter study of patients with MOGAD suggests that maintenance immunotherapy reduces recurrent CNS demyelinating attacks, with the lowest ARR being associated with maintenance IVIG therapy. Traditional MS disease-modifying agents appear to be ineffective. Prospective randomized controlled studies are required to validate these conclusions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000009758

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 233

Metadata

Authors
Chen, J. J., Flanagan, E. P., Bhatti, M. T., Jitprapaikulsan, J., Dubey, D., Lopez Chiriboga, A. (. S., Fryer, J. P., Weinshenker, B. G., McKeon, A., Tillema, J.-M., Lennon, V. A., Lucchinetti, C. F., Kunchok, A., McClelland, C. M., Lee, M. S., Bennett, J. L., Pelak, V. S., Van Stavern, G., Adesina, O.-O. O., Eggenberger, E. R., Acierno, M. D., Wingerchuk, D. M., Lam, B. L., Moss, H., Beres, S., Gilbert, A. L., Shah, V., Armstrong, G., Heidary, G., Cestari, D. M., Stiebel-Kalish, H., & Pittock, S. J.
Venue
Neurology
Published
2020-07-14
Volume
95
Issue
2
Pages
e111-e120
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W3036213479
Cited by
233
References
1
FWCI
19.74
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. https://app.cochat.ai/papers/10.1212/wnl.0000000000009758
The paper
Chen, J. J., Flanagan, E. P., Bhatti, M. T., Jitprapaikulsan, J., Dubey, D., Lopez Chiriboga, A. (. S., Fryer, J. P., Weinshenker, B. G., McKeon, A., Tillema, J.-M., Lennon, V. A., Lucchinetti, C. F., Kunchok, A., McClelland, C. M., Lee, M. S., Bennett, J. L., Pelak, V. S., Van Stavern, G., Adesina, O.-O. O., . . . Pittock, S. J. (2020). Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. https://doi.org/10.1212/wnl.0000000000009758

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.